PE20010600A1 - Derivados de bencimidazolonas que tienen afinidad para receptores mezclados de serotonina y dopamina - Google Patents
Derivados de bencimidazolonas que tienen afinidad para receptores mezclados de serotonina y dopaminaInfo
- Publication number
- PE20010600A1 PE20010600A1 PE2000000977A PE0009772000A PE20010600A1 PE 20010600 A1 PE20010600 A1 PE 20010600A1 PE 2000000977 A PE2000000977 A PE 2000000977A PE 0009772000 A PE0009772000 A PE 0009772000A PE 20010600 A1 PE20010600 A1 PE 20010600A1
- Authority
- PE
- Peru
- Prior art keywords
- ona
- piperazin
- trifluoromethyl
- hydroxy
- phenyl
- Prior art date
Links
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 title abstract 4
- 229940076279 serotonin Drugs 0.000 title abstract 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 title 2
- 229960003638 dopamine Drugs 0.000 title 1
- -1 3-TRIFLUOROMETHYL-PHENYL Chemical class 0.000 abstract 4
- 239000002253 acid Substances 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 abstract 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 abstract 1
- 102000015554 Dopamine receptor Human genes 0.000 abstract 1
- 108050004812 Dopamine receptor Proteins 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 150000007513 acids Chemical class 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 229910052796 boron Inorganic materials 0.000 abstract 1
- 238000010494 dissociation reaction Methods 0.000 abstract 1
- 230000005593 dissociations Effects 0.000 abstract 1
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical compound C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 230000001568 sexual effect Effects 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
SE REFIERE A 1,3-DIHIDROBENCIMIDAZOL-2-ONA SUSTITUIDOS DE FORMULA I, DONDE R1, R2, R3, R4 SON H, OH, CON LA CONDICION QUE R1, R2, R3, R4 NO SON A LA VEZ H; SON COMPUESTOS PREFERIDOS 5-HIDROXI-1-{2-[4-(3-TRIFLUOROMETIL-FENIL)-PIPERAZIN-1-IL]ETIL}-1,3-DIHIDROBENCIMIDAZOL-2-ONA, 6-HIDROXI-1-{2-[4-(3-TRIFLUOROMETIL-FENIL)-PIPERAZIN-1-IL]-ETIL}-1,3-DIHIDROBENCIMIDAZOL-2-ONA, 4-HIDROXI-1-{2-[4-(3-TRIFLUOROMETIL-FENIL)-PIPERAZIN-1-IL]-ETIL}-1,3-DIHIDROBENCIMIDAZOL-2-ONA, 7-HIDROXI-1-{2-[4-(3-TRIFLUOROMETIL-FENIL)PIPERAZIN-1-IL]-ETIL}-1,3-DIHIDROBENCIMIDAZOL-2-ONA, 1-{2-[4-(4-HIDROXI-5-TRIFLUOROMETIL-FENIL-PIPERAZIN-1-IL]-ETIL}-1,3-DIHIDROBENCIMIDAZOL-2-ONA, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION QUE COMPRENDE LA LIBERACION DEL GRUPO HIDROXI POR DISOCIACION DEL GRUPO PROTECTOR, LA DESPROTECCION DEL GRUPO HIDROXI SE DA POR TRATAMIENTO CON ACIDOS ACUOSOS FUERTES COMO ACIDO BROMHIDRICO A ALTAS TEMPERATURAS O POR TRATAMIENTO CON DERIVADOS DE BORO (BBr3) A BAJAS TEMPERATURAS EN DISOLVENTES CLORADOS. LOS COMPUESTOS I SE FIJAN A LOS RECEPTORES DE SEROTONINA Y DOPAMINA Y PUEDEN SER UTILES PARA EL TRATAMIENTO DE TRASTORNOS DEL SNC COMO DEPRESION, ESQUIZOFRENIA, ENFERMEDAD DE PARKINSON, ANSIEDAD, PERTURBACIONES DEL SUENO, TRASTORNOS SEXUALES
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT1999MI001964A IT1313625B1 (it) | 1999-09-22 | 1999-09-22 | Derivati benzimidazolonici aventi affinita' mista per i recettori diserotonina e dopamina. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20010600A1 true PE20010600A1 (es) | 2001-06-04 |
Family
ID=11383635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2000000977A PE20010600A1 (es) | 1999-09-22 | 2000-09-20 | Derivados de bencimidazolonas que tienen afinidad para receptores mezclados de serotonina y dopamina |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US6281218B1 (es) |
| EP (1) | EP1218352B1 (es) |
| JP (2) | JP4989002B2 (es) |
| AR (1) | AR025739A1 (es) |
| AT (1) | ATE266644T1 (es) |
| AU (1) | AU7653700A (es) |
| CA (1) | CA2381819C (es) |
| CO (1) | CO5210864A1 (es) |
| DE (1) | DE60010732T2 (es) |
| DK (1) | DK1218352T3 (es) |
| ES (1) | ES2220541T3 (es) |
| IT (1) | IT1313625B1 (es) |
| MX (1) | MXPA02001986A (es) |
| PE (1) | PE20010600A1 (es) |
| PT (1) | PT1218352E (es) |
| WO (1) | WO2001021593A1 (es) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1313625B1 (it) * | 1999-09-22 | 2002-09-09 | Boehringer Ingelheim Italia | Derivati benzimidazolonici aventi affinita' mista per i recettori diserotonina e dopamina. |
| US7183410B2 (en) * | 2001-08-02 | 2007-02-27 | Bidachem S.P.A. | Stable polymorph of flibanserin |
| US20030060475A1 (en) * | 2001-08-10 | 2003-03-27 | Boehringer Ingelheim Pharma Kg | Method of using flibanserin for neuroprotection |
| UA78974C2 (en) * | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
| US10675280B2 (en) | 2001-10-20 | 2020-06-09 | Sprout Pharmaceuticals, Inc. | Treating sexual desire disorders with flibanserin |
| US7033345B2 (en) * | 2002-05-21 | 2006-04-25 | Advanced Cardiovascular Systems, Inc. | Deflectable microimplant delivery system |
| US20040048877A1 (en) * | 2002-05-22 | 2004-03-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions containing flibanserin |
| WO2005021545A1 (en) * | 2003-09-03 | 2005-03-10 | Galapagos Nv | IMIDAZO[1,5-a]PYRIDINE OR IMIDAZO[1,5-a]PIPERIDINE DERIVATIVES AND THEIR USE FOR THE PREPARATION OF MEDICAMENT AGAINST 5-HT2A RECEPTOR-RELATED DISORDERS |
| US20050215589A1 (en) * | 2003-09-03 | 2005-09-29 | Roger Crossley | Inhibitors of 5-HT2A receptor |
| TW200533348A (en) * | 2004-02-18 | 2005-10-16 | Theravance Inc | Indazole-carboxamide compounds as 5-ht4 receptor agonists |
| US7728006B2 (en) * | 2004-04-07 | 2010-06-01 | Theravance, Inc. | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists |
| TWI351282B (en) | 2004-04-07 | 2011-11-01 | Theravance Inc | Quinolinone-carboxamide compounds as 5-ht4 recepto |
| US8309575B2 (en) | 2004-04-07 | 2012-11-13 | Theravance, Inc. | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists |
| WO2005102342A1 (en) * | 2004-04-22 | 2005-11-03 | Boehringer Ingelheim International Gmbh | New pharmaceutical compositions for the treatment of sexual disorders ii |
| US20050239798A1 (en) * | 2004-04-22 | 2005-10-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | Method for the treatment of premenstrual and other female sexual disorders |
| US20060025420A1 (en) * | 2004-07-30 | 2006-02-02 | Boehringer Ingelheimn International GmbH | Pharmaceutical compositions for the treatment of female sexual disorders |
| CA2576812A1 (en) * | 2004-09-03 | 2006-03-09 | Boehringer Ingelheim International Gmbh | Method for the treatment of attention deficit hyperactivity disorder |
| ES2332808T3 (es) * | 2004-11-05 | 2010-02-12 | Theravance, Inc. | Compuestos agonistas del receptor 5-ht4. |
| JP5042028B2 (ja) * | 2004-11-05 | 2012-10-03 | セラヴァンス, インコーポレーテッド | キノリノン−カルボキサミド化合物 |
| US7419989B2 (en) * | 2004-12-22 | 2008-09-02 | Theravance, Inc. | Indazole-carboxamide compounds |
| NZ560828A (en) * | 2005-03-02 | 2011-01-28 | Theravance Inc | Quinolinone compounds as 5-HT4 receptor agonists |
| WO2006096439A2 (en) * | 2005-03-04 | 2006-09-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases |
| EP1858516A1 (en) * | 2005-03-04 | 2007-11-28 | Boehringer Ingelheim International GmbH | Pharmaceutical compositions for the treatment and/or prevention of depression |
| EP1858515A2 (en) * | 2005-03-04 | 2007-11-28 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders |
| EP1904182A2 (en) * | 2005-05-06 | 2008-04-02 | Boehringer Ingelheim International GmbH | Method for the treatment of drug abuse with flibanserin |
| WO2006125041A1 (en) * | 2005-05-19 | 2006-11-23 | Boehringer Ingelheim International Gmbh | Method for the treatment of sexual dysfunctions due to medical conditions |
| JP2008540673A (ja) * | 2005-05-19 | 2008-11-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 薬剤誘発性性機能不全の治療方法 |
| ATE495171T1 (de) * | 2005-06-07 | 2011-01-15 | Theravance Inc | Benzimidazoloncarbonsäureamidverbindungen als agonisten des 5-ht4-rezeptors |
| US8227476B2 (en) | 2005-08-03 | 2012-07-24 | Sprout Pharmaceuticals, Inc. | Use of flibanserin in the treatment of obesity |
| US20070123540A1 (en) * | 2005-10-29 | 2007-05-31 | Angelo Ceci | Sexual desire enhancing medicaments comprising benzimidazolone derivatives |
| EP1945214A1 (en) * | 2005-10-29 | 2008-07-23 | Boehringer Ingelheim International GmbH | Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders |
| US20070105869A1 (en) * | 2005-11-08 | 2007-05-10 | Stephane Pollentier | Use of flibanserin for the treatment of pre-menopausal sexual desire disorders |
| MY143574A (en) * | 2005-11-22 | 2011-05-31 | Theravance Inc | Carbamate compounds as 5-ht4 receptor agonists |
| WO2007096300A1 (en) * | 2006-02-20 | 2007-08-30 | Boehringer Ingelheim International Gmbh | Benzimidazolone derivatives for the treatment of urinary incontinence |
| CA2649938A1 (en) * | 2006-05-09 | 2007-11-15 | Boehringer Ingelheim International Gmbh | Use of flibanserin for the treatment of post-menopausal sexual desire disorders |
| ES2336719T3 (es) | 2006-06-30 | 2010-04-15 | Boehringer Ingelheim International Gmbh | Flibanserina para el tratamiento de la incontinencia urinaria y las enfermedades relacionadas. |
| US20090318469A1 (en) * | 2006-07-14 | 2009-12-24 | Boehringer Ingelheim International Gmbh | Use of Flibanserin for the Treatment of Sexual Disorders in Females |
| JP5793828B2 (ja) * | 2006-08-14 | 2015-10-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | フリバンセリンの製剤及びその製造方法 |
| CL2007002214A1 (es) * | 2006-08-14 | 2008-03-07 | Boehringer Ingelheim Int | Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp |
| AR062321A1 (es) * | 2006-08-25 | 2008-10-29 | Boehringer Ingelheim Int | Sistema de liberacion controlada y metodo para fabricarlo |
| WO2008061968A1 (en) * | 2006-11-22 | 2008-05-29 | Boehringer Ingelheim International Gmbh | Benzimidazolone derivates in the treatment of pulmonary arterial hypertension |
| EP2097389B1 (en) * | 2006-12-20 | 2011-09-14 | Boehringer Ingelheim International GmbH | Sulfated benzimidazolone derivatives having mixed serotonine receptor affinity |
| JP5087011B2 (ja) * | 2007-01-23 | 2012-11-28 | 馨 井上 | 眼疾患モデル用非ヒト動物 |
| PE20091188A1 (es) | 2007-09-12 | 2009-08-31 | Boehringer Ingelheim Int | Compuesto 1-[2-(4-(3-trifluorometil-fenil)piperazin-1-il)etil]-2,3-dihidro-1h-benzimidazol-2-ona (flibanserina), sus sales de adicion y composiciones farmaceuticas que los contienen |
| WO2009092720A1 (en) * | 2008-01-24 | 2009-07-30 | Neurosearch A/S | 4-phenyl-piperazin-1-yl-alkyl-benzoimidazol-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| CA2686480A1 (en) | 2008-12-15 | 2010-06-15 | Boehringer Ingelheim International Gmbh | New salts |
| BRPI1003506B1 (pt) | 2010-09-24 | 2019-12-03 | Ache Int Bvi Ltd | composto alquil-piperazino-fenil-4(3h)quinazolinonas e uso do composto alquil-piperazino-fenil-4(3h)quinazolinonas associado aos receptores serotoninérgicos 5-ht1a e 5-ht2a |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1251144B (it) * | 1991-07-30 | 1995-05-04 | Boehringer Ingelheim Italia | Derivati del benzimidazolone |
| IT1313625B1 (it) * | 1999-09-22 | 2002-09-09 | Boehringer Ingelheim Italia | Derivati benzimidazolonici aventi affinita' mista per i recettori diserotonina e dopamina. |
-
1999
- 1999-09-22 IT IT1999MI001964A patent/IT1313625B1/it active
-
2000
- 2000-08-08 US US09/634,120 patent/US6281218B1/en not_active Expired - Lifetime
- 2000-09-12 AT AT00965975T patent/ATE266644T1/de active
- 2000-09-12 EP EP00965975A patent/EP1218352B1/en not_active Expired - Lifetime
- 2000-09-12 CA CA002381819A patent/CA2381819C/en not_active Expired - Fee Related
- 2000-09-12 DE DE60010732T patent/DE60010732T2/de not_active Expired - Lifetime
- 2000-09-12 JP JP2001524972A patent/JP4989002B2/ja not_active Expired - Fee Related
- 2000-09-12 AU AU76537/00A patent/AU7653700A/en not_active Abandoned
- 2000-09-12 PT PT00965975T patent/PT1218352E/pt unknown
- 2000-09-12 ES ES00965975T patent/ES2220541T3/es not_active Expired - Lifetime
- 2000-09-12 MX MXPA02001986A patent/MXPA02001986A/es active IP Right Grant
- 2000-09-12 WO PCT/EP2000/008891 patent/WO2001021593A1/en not_active Ceased
- 2000-09-12 DK DK00965975T patent/DK1218352T3/da active
- 2000-09-20 PE PE2000000977A patent/PE20010600A1/es not_active Application Discontinuation
- 2000-09-21 CO CO00071863A patent/CO5210864A1/es not_active Application Discontinuation
- 2000-09-22 AR ARP000104963A patent/AR025739A1/es unknown
-
2011
- 2011-10-14 JP JP2011226651A patent/JP2012067105A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP1218352B1 (en) | 2004-05-12 |
| CO5210864A1 (es) | 2002-10-30 |
| US6281218B1 (en) | 2001-08-28 |
| EP1218352A1 (en) | 2002-07-03 |
| PT1218352E (pt) | 2004-09-30 |
| DE60010732D1 (de) | 2004-06-17 |
| ITMI991964A1 (it) | 2001-03-22 |
| JP2012067105A (ja) | 2012-04-05 |
| CA2381819A1 (en) | 2001-03-29 |
| CA2381819C (en) | 2007-03-13 |
| AR025739A1 (es) | 2002-12-11 |
| JP2003509496A (ja) | 2003-03-11 |
| DK1218352T3 (da) | 2004-06-28 |
| ATE266644T1 (de) | 2004-05-15 |
| ES2220541T3 (es) | 2004-12-16 |
| JP4989002B2 (ja) | 2012-08-01 |
| DE60010732T2 (de) | 2005-05-25 |
| IT1313625B1 (it) | 2002-09-09 |
| ITMI991964A0 (it) | 1999-09-22 |
| MXPA02001986A (es) | 2002-10-31 |
| WO2001021593A1 (en) | 2001-03-29 |
| AU7653700A (en) | 2001-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20010600A1 (es) | Derivados de bencimidazolonas que tienen afinidad para receptores mezclados de serotonina y dopamina | |
| MY132565A (en) | Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar) | |
| PE20020228A1 (es) | Compuestos organicos como inhibidores de 3',5' guanosin monofosfato ciclico fosfodiesterasa | |
| BRPI0415657A (pt) | derivados de alcanamina de diidrobenzofuranila como agonistas de 5ht2c | |
| PE20030549A1 (es) | Derivados de 1,6-naftiridina y su uso para el tratamiento de la diabetes y transtornos relacionados | |
| PE20001600A1 (es) | Derivados de 1,4-diazabiciclo (3.3.2) nonan-4-carboxilatos y carboxamidas, su preparacion y su aplicacion en terapeutica | |
| PE20071325A1 (es) | Derivados de n-heteroaril-carboxamidas triciclicas que contienen un resto bencimidazol, su preparacion y su aplicacion en terapeutica | |
| AR036114A1 (es) | Tetrahidroimidazol[1,2-a]pirazinas y tetrahidrotriazol[4,3-a]pirazinas como inhibidores de la dipeptidil peptidasa utiles para el tratamiento o la prevencion de la diabetes | |
| PE20000728A1 (es) | Heterociclos 4-bencil piperidina alquilsulfoxido y su uso como antagonistas receptores subtipo-selectivo nmda | |
| PE20121640A1 (es) | Derivados de pirazina como inhibidores de bace | |
| MX2007013021A (es) | Derivados de benzofuranil-alcanamina y usos de los mismos como agonistas de 5-ht2c. | |
| PE20030715A1 (es) | Derivados de benzotiazol sustituidos con piridona como ligandos del receptor a2a de adenosina | |
| NZ525700A (en) | Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5HT-2 receptor | |
| PE49395A1 (es) | Compuestos diazabiciclicos, antagonistas de neurocinina | |
| PE20010039A1 (es) | Derivados de esteres del acido carbamico como agonistas y/o antagonistas del receptor metabotropico del glutamato | |
| ES2094843T3 (es) | Bencisotiazol- y bencisoxazol-3-carboxamidas, un procedimiento para su preparacion y su empleo como medicamentos antipsicoticos. | |
| PE91798A1 (es) | Pirrolicarboxanilidas condensadas: utiles como ligandos receptores | |
| PE20000170A1 (es) | Derivados benzosulfonas | |
| PE20060949A1 (es) | Derivados fusionados de pirazol como agonistas del receptor de niacina | |
| PE20001583A1 (es) | Derivados de la 1-arenosulfonil-2-arilo-pirrolidina y de la piperidina | |
| CO5680438A2 (es) | Uso de derivados de ciclotiocarbamato en tratamiento de condiciones relacionadas con hormonas | |
| PE20030718A1 (es) | Lactamas como antagonistas de taquiquininas | |
| PE20080364A1 (es) | Acido bifenilcarboxilicos substituidos y sus derivados como moduladores de la actividad de la gamma-secretasa | |
| PE106299A1 (es) | Derivados del 2-(4-aril o heteroaril-piperazin-1-ilmetil)-1h-indol | |
| CA2417082A1 (en) | New benzimidazolone derivatives displaying affinity at the serotonin and dopamine receptors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |